Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI +3.15%55 Capex-to-Operating-Income is 0.00 as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 55/100 and a GF Value™ of €2.81 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 500 Drug Manufacturers companies, Euroapi ranks worse than 99.4% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Euroapi Capex-to-Operating-Income Related Terms
Euroapi Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Euroapi's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:EAPI vs ZTS, UTHR, VTRS: Capex-to-Operating-Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi Capex-to-Operating-Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Euroapi's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.00 mean?
Euroapi (XPAR:EAPI) has a Capex-to-Operating-Income of 0.00 as of Dec. 2025. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Euroapi and its competitors. Over the past decade, Euroapi's Capex-to-Operating-Income has ranged from 6.18 to 59.07. According to the industry distribution chart, Euroapi ranks #497 out of 500 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Euroapi's Capex-to-Operating-Income too high?
Euroapi's current Capex-to-Operating-Income is 0.00. Over the past 10 years, this metric has ranged from a low of 6.18 to a high of 59.07. Based on the distribution chart, Euroapi ranks #497 out of 500 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Euroapi has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Capex-to-Operating-Income compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #497 out of 500 companies for Capex-to-Operating-Income. This places Euroapi in the lower half of its industry. The industry median Capex-to-Operating-Income is 0.41. Historically, Euroapi's own Capex-to-Operating-Income has ranged from 6.18 to 59.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Drug Manufacturers company?
The median Capex-to-Operating-Income among Drug Manufacturers companies is 0.41, based on 500 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Income is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current Capex-to-Operating-Income is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.81, compared to a current price of €0.85 — trading 69.7% below its estimated fair value. The current Capex-to-Operating-Income is 0.00. Euroapi's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Capex-to-Operating-Income is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €0.85 is trading 69.7% below its estimated GF Value™ of €2.81.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
Capex-to-Operating-Income: 0.00
GF Value™: €2.81 vs. price of €0.85 (69.7% below fair value)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
55GF Score
Get the complete analysis for XPAR:EAPI
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
